The authors mentioned several limitations. Too few studies reported on PrEP use in heterosexuals or injection drug users, so analyses could not be conducted for these groups. In addition, PrEP use was self-reported in all studies and may indicate past but not current use. Finally, results are limited to published studies only and may not necessarily represent actual rates in the community.
• Review of study data showed self-reported PrEP use has grown between 1.6 times per year globally and 1.8 times per year in the US since FDA approval in 2012
• The growth rate of PrEP use among MSM in the US is even higher and has approximately doubled each year since 2012
• Almost 1 in 6 US-based study participants and almost 1 in 4 MSM who met CDC’s PrEP indications reported ever using PrEP by 2016
1. Kamitani E, Wichser ME, Adegbite AH, et al. Increasing prevalence of self-reported HIV pre-exposure prophylaxis (PrEP) use in published surveys - a systematic review and meta-analysis. AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001983.
2. Mera Giler R, Magnuson D, Trevor H, et al. Changes in Truvada (TVD) for HIV pre-exposure prophlaxis (PrEP) unilization in the United States: (2012-2016). Presented at the 9th IAS Conference on HIV Science (IAS 2017). Paris, France; 2017. Accessed August 20, 2018.
3. Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1291-1295. doi: 10.15585/mmwr.mm6446a4.